Investing Profile

John McKearn

InvestorVC

Venture Capital / BioPharma R&D

Photo of John McKearn, Managing Director at RiverVest

Signal uses Gmail to reveal intro paths. Email content is never read.

Sign in with Google →
cb
RiverVest Managing Director
$100K - $10.0M
$1M
10
$184.4M
CompanyStageDateRound SizeTotal Raised
Wugen
Series BJul 2021$170M
$170M
Co-investors: Bali Muralidhar (Abingworth)
Tioma Therapeutics
Series AAug 2016$86M
$86M
Co-investors: Peter Moldt (Novo Ventures), Jill carroll (SR One), Carole Nuechterlein (Roche Venture Fund)
Allakos
Series ASep 2014$10M
Series AAug 2014$25M
$130M
Co-investors: Paul Walker (New Enterprise Associates (NEA)), Farah Champsi (InterWest)
Otonomy
Series DApr 2014$49M
Series CSep 2013$46M
Series BAug 2010$39M
$140M
Co-investors: Jay Lichter (Avalon Ventures), Peter Bisgaard (Pivotal bioVenture Partners), Brian Dovey (Domain Associates), Bill Harrington (Osage University Partners), Niall O’Donnell (RiverVest), Heather Preston (Pivotal bioVenture Partners)
ZS Pharma
Series DMar 2014$55M
Series COct 2012$46M
$100M
Lumena Pharmaceuticals
Series AMay 2013$23M
$68M
Co-investors: Ed Mathers (New Enterprise Associates (NEA)), Niall O’Donnell (RiverVest)